Loss of G2032R Resistance Mutation Upon Chemotherapy Treatment Enables Successful Crizotinib Rechallenge in a Patient With ROS1-Rearranged NSCLC.
This case is a proof of concept that re-challenging with crizotinib after intervening chemotherapy is feasible in ROS1-rearranged NSCLC with acquired resistance.
Read full article here.